Successful applications to date for access to the free TRANSVAC services
Access to the free TRANSVAC services has been approved by the Scientific Advisory Committee and the User Selection Panel for the following projects:
Results of the first call for applications (1101-1)
Results of the second call for applications (1104-2)
Results of the third call for applications (1107-3)
Results of the fourth call for applications (1110-4)
Results of the fifth call for applications (1201-5)
Results of the sixth call for applications (1204-6)
Results of the seventh call for applications (1207-7)
Results of the eighth call for applications (1210-8)
Results of the ninth call for applications (1301-9)
Results of the first call for applications (1101-1)
| Applicant / User | Access granted to | Access units provided | Project | |
| 1 | Statens Serum Institut (SSI), Copenhagen, Denmark Prof. Peter Andersen |
Experimental Non-human primate model facility, Biomedical Primate Research Centre, The Netherlands |
18 | CD4/8 responses by CAF Evaluation of the immunogenicity and tolerability of an antigenic formulation in CD4 T-cell inducing CAF01 and CD4/CD8 T-cell inducing CAF05 adjuvant upon simultaneous muco-parenteral compared to traditional parenteral delivery in rhesus macaques |
| 2 | Themis Bioscience, Vienna, Austria Dr. Katrin Ramsauer |
ILLUMINA Deep Sequencing, Helmholtz Centre for Infection Research, Germany |
10 | MVDVAX A single tetravalent live attenuated recombinant Measles Virus Vaccine against DENGUE |
| 3 | Université de Lyon, Faculté de Médecine Saint Etienne, Lyon, France Dr. Stéphane Paul |
Vaccine formulation laboratory World Health Organization Collaborating Centre - University of Lausanne, Switzerland |
9 | MUCOSTIM Evaluation of adjuvant formulation in the induction of mucosal immune responses against HIV after subcutaneous or intramuscular vaccination with p24 antigen encoated on PLA particles |
| 4 |
Trinity College, Dublin, Ireland |
Vaccine formulation laboratory, World Health Organization Collaborating Centre - University of Lausanne, Switzerland |
5 | TARGET-PART-QS21 Development of potent mucosal vaccines by combining an effective targeting agent with immunostiumlatory particulate adjuvants |
Results of the second call for applications (1104-2)
| Applicant / User |
Access granted to | Access units provided | Project | |
| 5 | INSERM, Institut Pasteur de Lille, Lille, France Dr. Jean-Claude Sirard |
AGILENT Microarrays,Max Planck Institute for Infection Biology, Germany | 2 | FLAGMARK Transcriptional analysis of flagellin-mediated adjuvant activity: defining predictive biomarkers of efficacy in blood samples |
| 6 | The Jenner Institute, Oxford, United Kingdom Prof. Adrian Hill |
Vaccine formulation laboratory,World Health Organization Collaborating Centre - University of Lausanne, Switzerland | 5 | CombiVAX Combination (vector-adjuvant-protein) vaccine against malaria |
| 7 | University College Cork, Cork, Ireland Dr. Anne Moore |
Large Animal studies,Central Veterinary Institute of Wageningen, The Netherlands | 2 | ImmuPatch Pre-clinical Testing of Influenza Vaccine Incorporated in Dissolvable ImmuPatch Microneedle Arrays |
Results of the third call for applications (1107-3)
|
|
Applicant / User | Access granted to | Access units provided | Project |
| 8 |
Academy of Sciences of Czech Republic, Ceske Budejovice, Czech Republic |
ILLUMINA Deep Sequencing, Helmholtz Centre for Infection Research, Germany |
60 |
DUALVACANTIRICINUS |
| 9 |
Glycovaxyn, Schlieren, Switzerland |
Experimental murine validation platform,Helmholtz Centre for Infection Research, Germany |
1 |
GVXN Pn4-EPA_1 |
| 10 |
Institute of Immunology Inc. Zagreb, Zagreb, Croatia |
ILLUMINA Deep Sequencing, Helmholtz Centre for Infection Research, Germany |
36 |
MUMPSVAC |
| 11 |
Biomedical Primate Research Centre, Rijswijk, The Netherlands |
Vaccine formulation laboratory, World Health Organization Collaborating Centre - University of Lausanne, Switzerland |
9 |
rAMA1_VAC |
Results of the fourth call for applications (1110-4)
No successful application.
Results of the fifth call for applications (1201-5)
| Applicant / User |
Access granted to | Access units provided | Project | |
| 12 | Animal Health and Veterinary Laboratory Agency,New Haw, United Kingdom Dr. Bernardo Villarreal-Ramos |
ILLUMINA Deep Sequencing, Helmholtz Centre for Infection Research, Germany | 30 | RNA seq in bovine TBRNA sequencing for the discovery of potential biomarkers of disease/protection in bovine TB and their potential use as model for TB in humans |
| 13 | University of Zaragoza,Zaragoza, Spain Prof. Carlos Martin |
AGILENT Microarrays,Max Planck Institute for Infection Biology, Germany | 9 | MTBVAC-TS MTBVAC transcriptional signature of phase I BCG/MTBVAC-vaccinated subjects |
Results of the sixth call for applications (1204-6)
| Applicant / User | Access granted to | Access units provided | Project | |
| 14 | Scientific Insitute of Public Health, Brussels,Belgium Dr. Kris Huygen |
Large Animal studies, Central Veterinary Institute of Wageningen, The Netherlands |
3 | BCG-p85A-combo Increasing the protective efficacy of M. bovis BCG vaccine by combined vaccination with plasmid DNA encoding the mycolyl-transferase Ag85A (Rv3804c). |
| 15 | INSERM, Lille, France Dr. Jean-Claude Sirard |
Vaccine formulation laboratory World Health Organization Collaborating Centre - University of Lausanne, Switzerland |
14 | FLAGTRIAL From mice to appropriate model of human intradermal immunization: efficacy and signature of the TLR5 agonist flagellin in Sus scrofa pigs |
| 16 | INSERM, Lille, France Dr. Jean-Claude Sirard |
Large Animal studies, Central Veterinary Institute of Wageningen, The Netherlands |
2 | FLAGTRIAL From mice to appropriate model of human intradermal immunization: efficacy and signature of the TLR5 agonist flagellin in Sus scrofa pigs |
| 17 | INSERM, Lille, France Dr. Jean-Claude Sirard |
AGILENT Microarrays, Max Planck Institute for Infection Biology, Germany |
1 | FLAGTRIAL From mice to appropriate model of human intradermal immunization: efficacy and signature of the TLR5 agonist flagellin in Sus scrofa pigs |
| 18 | Medical Research Council Clinical Trials Unit, London, United Kingdom Dr. Sarah Joseph |
ILLUMINA Deep Sequencing, Helmholtz Centre for Infection Research, Germany |
40 | HIV_vaccine_breakthrough Pilot study to deep sequence HIV breakthrough infections that have occurred during HIV vaccine trials conducted by the TaMoVac consortium and partner institutions |
Results of the seventh call for applications (1207-7)
| Applicant / User | Access granted to | Access units provided | Project | |
| 19 | Barcelona Centre for International Health Research, Barcelona, Spain Dr. Carlota Dobano Lázaro |
AFFYMETRIX Microarrays, University of Regensburg, Germany |
2 |
BACHMI01_VacGeneExp
Controlled human malarial infection: a tool to identify key immunological responses and new antigens for vaccine development |
| 20 | INSERM, Lille, France Dr. Camille Locht |
AGILENT Microarrays, Max Planck Institute for Infection Biology, Germany |
3 |
BPZE1-Immuntranscript |
| 21 |
Statens Serum Institut, Copenhagen, Denmark |
Stable Reference Reagents, Health Protection Agency, National Institute for Biological Standards and Control, UK |
44 |
CD4-8 resp by CAF |
| 22 |
Institute of Pharmacology and Structural Biology/CNRS, Toulouse, France |
Vaccine formulation laboratory World Health Organization Collaborating Centre - University of Lausanne, Switzerland |
8 | LipTBvaccine Improving the stability of DDA liposomes to deliver lipid antigens |
| 23 |
Poznan University School of Medical Science, Poznan, Poland |
AFFYMETRIX Microarrays, University of Regensburg, Germany |
1 | TRANSMELVAX Transcriptom analysis of gene modified therapeutic melanoma cellular vaccine |
Results of the eighth call for applications (1210-8)
| Applicant / User | Access granted to | Access units provided | Project | |
| 24 | Statens Serum Institut, Copenhagen, Denmark Dr. Dennis Christensen |
AFFYMETRIX Microarrays, University of Regensburg, Germany |
5 |
Transc-rep-prof-by-CAF
Transcriptional response profiles in cynomolgus macaques upon CAF01- or CAF09-formulated parenteral and mucoparenteral vaccination |
| 25 |
Centro Nacional de Biotecnología, Madrid, Spain |
Rhesus Macaque Models, Health Protection Agency, Centre for Emergency Preparedness and Response, UK | 2 | C6LVAC Immunogenicity of an HIV/AIDS vaccine candidate lacking vaccinia virus gene C6L in non-human primates |
Results of the ninth call for applications (1301-9)
No successful application.
|
18 |
|
10 |
|
9 |
|
5 |